Virax Biolabs Group Ltd. Class A share price logo

Virax Biolabs Group Ltd. Class A

NASDAQ: VRAX

$2.77

-0.14

(-4.81%)

as on

Virax Biolabs Group Ltd. Class A Stock Performance

as on August 27, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $2.73
    $2.94
    downward going graph

    1.44%

    Downside

    6.14%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.50
    $21.75
    downward going graph

    9.75%

    Downside

    685.20%

    Upside

    downward going graph

Virax Biolabs Group Ltd. Class A share price movements today

Previous Close
$2.91
Open
$2.94
Volume
564.7K
Market Cap
$2.4M
Day's Low - High
$2.73 - $2.94
52 Week Low - High
$2.50 - $21.75

Virax Biolabs Group Ltd. Class A Historical Returns

1 Month Return
-6.13 %
3 Month Return
-46.9 %
1 Year Return
-80.43 %
3 Year Return
-96.91 %
5 Year Return
0 %

Virax Biolabs Group Ltd. Class A Stock Fundamentals & Key Indicators

Check Virax Biolabs Group Ltd. Class A market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.4M

EPS (TTM)

-10

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-78.65%

Virax Biolabs Group Ltd. Class A vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Virax Biolabs Group Ltd. Class A with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Virax Biolabs Group Ltd. Class A image
Virax Biolabs Group Ltd. Class A
NA$2.4MNANA0.00%NA
Revolution Medicines image
Revolution Medicines
BUY$45.3B641.42%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$138.8B176.54%31.9535.00%NA
Moderna image
Moderna
BUY$55.4B-58.45%NA-141.43%NA
Regeneron image
Regeneron
BUY$85.3B25.67%20.6227.87%44.39%

Stock Returns calculator for Virax Biolabs Group Ltd. Class A Stock including INR - Dollar returns

The Virax Biolabs Group Ltd. Class A stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Virax Biolabs Group Ltd. Class A investment value today

Current value as on today

₹20,279

Returns

-₹79,721

(-79.72%)

Returns from Virax Biolabs Group Ltd. Class A Stock

-₹81,372 (-81.37%)

Dollar Impact

₹1,651 (+1.65%)

Indian Investors' Interest in Virax Biolabs Group Ltd. Class A Stock

Search interest for Virax Biolabs Group Ltd. Class A Stock has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-63% versus previous 30 day period

Virax Biolabs Group Ltd. Class A Quarterly Profit & Loss

All numbers in Millions USD

Jun 2022
Sep 2022
Dec 2022
Mar 2023
Sep 2023
Jun 2024
Sep 2024
Jun 2025
Sep 2025
Jun 2026
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-1
-1
-4
-4
-2
-3
-2
-3
-2
-6
EBITDA
-1
0
0
0
-2
-3
-2
-3
-2
-5
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-1
-1
-4
-4
-2
-3
-2
-3
-2
-5
Income Tax Expense
0
-1
-4
-4
0
0
0
-
0
0
Net Income
-1
-1
-4
-4
-2
-3
-2
-3
-2
-5
Net Profit Margin
1245.26%
-25062.69%
-143301.79%
-143301.79%
-3803.47%
-4784.70%
-55651.67%
-239827.29%
-145445.96%
-40439.10%

Virax Biolabs Group Ltd. Class A Annual Profit & Loss

All numbers in Millions USD

Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
0
0
-
0
0
0
0
Gross Profit
0
0
-
0
0
0
0
Operating Income
0
0
-1
-5
-6
-6
-6
EBITDA
0
0
0
-5
-6
-5
-5
Interest Expense
0
0
0
0
0
0
0
Depreciation
-
-
-
-
0
0
0
Income Before Tax
0
0
-1
-5
-6
-6
-5
Income Tax Expense
0
0
-1
0
0
0
0
Net Income
0
0
-1
-5
-6
-6
-5
Net Profit Margin
-802.13%
-525.75%
0.00%
-63748.32%
-4304.81%
-95739.17%
-40439.10%

Virax Biolabs Group Ltd. Class A Quarterly Cash Flow

All numbers in Millions USD

Sep 2022
Dec 2022
Mar 2023
Sep 2023
Jun 2024
Sep 2024
Jun 2025
Sep 2025
Jun 2026
Net Income
-1
-4
-4
-2
-3
-2
-3
-2
-5
Operating Cash Flow
-2
-1
-1
-3
-2
-1
-2
-2
-4
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
6
6
6
0
1
5
0
2
7
Change in Cash
4
4
4
-4
-1
3
-3
0
2

Virax Biolabs Group Ltd. Class A Annual Cash Flow

All numbers in Millions USD

Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Income
0
-1
-5
-6
-6
-5
Operating Cash Flow
0
0
-4
-6
-4
-4
Investing Cash Flow
0
0
0
-1
0
0
Financing Cash Flow
0
0
13
1
5
7
Change in Cash
0
0
9
-5
0
2

Global Institutional Holdings in Virax Biolabs Group Ltd. Class A

Funds
Holdings
Citadel Advisors Llc
0%
Advisor Group Holdings, Inc.
0%
NATIONAL BANK OF CANADA /FI/
0%
XTX Topco Ltd
0%
TWO SIGMA SECURITIES, LLC
0%
See all

Virax Biolabs Group Ltd. Class A News & Key Events

  • img

    Today's Timeline - 09 July

    Thu, 05:00 PM

    -

    Virax Biolabs announces exclusive supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets.

    Thu, 06:53 PM

    -

    Virax stock surges after revealing new commercial supply agreement with Fosun Diagnostics, expanding market reach.

    Thu, 08:01 PM

    -

    Virax stock triples as agreement opens access to Southeast Asian markets, driving potential revenue growth.

  • img

    Today's Timeline - 09 July

    Thu, 11:05 PM

    -

    Virax Biolabs exercises options for 548,000 shares, raising approximately $3.3 million for working capital.

Insights on Virax Biolabs Group Ltd. Class A

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 1.37K → 12.42K (in $), with an average increase of 50.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 33.7% return, outperforming this stock by 130.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 496.3% return, outperforming this stock by 577.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -2.33M → -5.02M (in $), with an average decrease of 114.8% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, VRAX stock has moved down by -19.7%

About Virax Biolabs Group Ltd. Class A

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.
OrganisationVirax Biolabs Group Ltd. Class A
HeadquartersBioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH
IndustryBiotechnology
CEOMr. James Foster
E-voting on sharesClick here to vote

Key Management of Virax Biolabs Group Ltd. Class A

Name

Title

Mr. James Foster

Chairman, CEO & Principal Accounting Officer

Dr. Nigel McCracken M.Sc., Ph.D.

COO & Director

Mr. Clement Monteil

Head of Scientific Research & Development

Ms. Lily Fu

Head of Supply Chain

FAQs

What is Virax Biolabs Group Ltd. Class A share price today?

Virax Biolabs Group Ltd. Class A share price today is $2.77 as on at the close of the market. Virax Biolabs Group Ltd. Class A share today touched a day high of $2.94 and a low of $2.73.

What is the 52 week high and 52 week low for Virax Biolabs Group Ltd. Class A share?

Virax Biolabs Group Ltd. Class A share touched a 52 week high of $21.75 on and a 52 week low of $2.50 on . Virax Biolabs Group Ltd. Class A stock price today i.e. is closed at $2.77,which is 87.26% down from its 52 week high and 10.80% up from its 52 week low.

What is Virax Biolabs Group Ltd. Class A's market capitalisation today?

Virax Biolabs Group Ltd. Class A market capitalisation is $0.00T as on .

How to invest in Virax Biolabs Group Ltd. Class A Stock (VRAX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Virax Biolabs Group Ltd. Class A on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Virax Biolabs Group Ltd. Class A Shares that will get you 0.5415 shares as per Virax Biolabs Group Ltd. Class A share price of $2.77 per share as on August 27, 2026 at 8:45 am IST.

What is the minimum amount required to buy Virax Biolabs Group Ltd. Class A Stock (VRAX) from India?

Indian investors can start investing in Virax Biolabs Group Ltd. Class A (VRAX) shares with as little as ₹95.402 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹954.02 in Virax Biolabs Group Ltd. Class A stock (as per the Rupee-Dollar exchange rate as on ). Based on Virax Biolabs Group Ltd. Class A share’s latest price of $2.77 as on August 27, 2026 at 8:45 am IST, you will get 3.6101 shares of Virax Biolabs Group Ltd. Class A. Learn more about fractional shares .